Skip to main content

Advertisement

Table 1 Patient characteristics

From: Pilot study of PET imaging of 124I-iodoazomycin galactopyranoside (IAZGP), a putative hypoxia imaging agent, in patients with colorectal cancer and head and neck cancer

Patient Tumor site Histologic subtype Differentiation TNM IAZGP (MBq) Imaging scheme IAZGP uptake Neoadjuvant therapy Response (%)
1 Pseudomyxoma peritonei Mucinous adenocarcinoma Moderate N/A 116 A (-) None N/A
2 Tonsil Squamous Moderate to poor cT1N2M0 108 A (-) Radiation NED
3 Tonsil Squamous Poor cT4N2M0 59 A (-) CRT NED
4 Tongue Squamous Poor cT1N1M0 160 B (-) CRT NED
5 Rectum Mucinous adenocarcinoma Poor pT4N2M0 148 B (-) CRT 95%
6 Rectum Adenocarcinoma Moderate pT3N0M1 141 B (-) Chemotherapy 50%
7 Rectum Adenocarcinoma Moderate pT3N0M0 150 B (-) CRT 60%
8 Rectum Adenocarcinoma Moderate cT4NxM1 159 B (-) Chemotherapy Progression
9 Supraglottic larynx Squamous Moderate cT3N2M0 157 B (-) CRT NED
10 Sigmoid Adenocarcinoma Moderate cTxN2M1 159 B (-) Chemotherapy Progression
  1. Serial whole-body, blood, and PET data were acquired for patients 1 to 10. Post-imaging clinical management and response are also shown. CRT chemoradiotherapy, NED no evidence of disease. Imaging schemes: A = 3, 18 to 24, and 48 h post 124I-IAZGP injection; B = 3, 6 to 8, and 24 h post 124I-IAZGP injection.